---
title: "Top 10 HK Stock Losers (1.5)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271482469.md"
description: "BUTONG GROUP(06090) fell 29.62%, with a trading turnover 32.5 Million HKD, and a year-to-date fell 32.3%. XUANZHUBIO-B(02575) fell 19.71%, with a trading turnover 31.9 Million HKD, and a year-to-date fell 25.7%. CLOUDBREAK-B(02592) fell 19.07%, with a trading turnover 38.4 Million HKD, and a year-to-date fell 29.8%."
datetime: "2026-01-05T08:30:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271482469.md)
  - [en](https://longbridge.com/en/news/271482469.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271482469.md)
---

# Top 10 HK Stock Losers (1.5)

Hang Seng Index has rose 0.03%, with a year-to-date rose 2.8%; Hang Seng TECH Index has rose 0.09%, with a year-to-date rose 4.1%.

BUTONG GROUP(06090) fell 29.62%, with a trading turnover 32.5 Million HKD, and a year-to-date fell 32.3%.

XUANZHUBIO-B(02575) fell 19.71%, with a trading turnover 31.9 Million HKD, and a year-to-date fell 25.7%.

CLOUDBREAK-B(02592) fell 19.07%, with a trading turnover 38.4 Million HKD, and a year-to-date fell 29.8%.

### Related Stocks

- [06090.HK](https://longbridge.com/en/quote/06090.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)
- [02592.HK](https://longbridge.com/en/quote/02592.HK.md)
- [06616.HK](https://longbridge.com/en/quote/06616.HK.md)
- [02577.HK](https://longbridge.com/en/quote/02577.HK.md)
- [02208.HK](https://longbridge.com/en/quote/02208.HK.md)
- [02431.HK](https://longbridge.com/en/quote/02431.HK.md)
- [01045.HK](https://longbridge.com/en/quote/01045.HK.md)
- [09678.HK](https://longbridge.com/en/quote/09678.HK.md)
- [01709.HK](https://longbridge.com/en/quote/01709.HK.md)

## Related News & Research

- [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md)
- [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/en/news/280309450.md)
- [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md)
- [Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib](https://longbridge.com/en/news/283291980.md)
- [Global New Material Flags 2025 Loss on Merck Deal Costs Despite Strong Revenue Growth](https://longbridge.com/en/news/279688011.md)